Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J

Share This Post